SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Barclays downgrade of Joby, citing cash burn and doubts about manufacturing capacity, is driving the selloff and comparisons with its upgraded rival Archer. Traders disagree over whether the concerns are justified or the downgrade is a shakeout, with some buying the dip and others moving toward Archer.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Abivaxs pullback is fueling debate over whether buyout hopes have outrun the near-term case for its ulcerative-colitis drug, obefazimod, despite positive Phase 3 data and a planned FDA filing. Bulls see value in the drugs potential and point to Crohns data as a future catalyst, while skeptics say the lack of a deal could leave the shares waiting on clinical and regulatory milestones; some also cite broader biotech weakness.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase is drawing attention as traders weigh persistent solar-sector pressure from higher borrowing costs and weaker residential demand against its developing IQ SST opportunity for AI data-center power. U.S. production progress and planned demonstrations and customer pilots have fueled rebound and short-squeeze speculation, while skeptics caution that the new business is still unproven and near-term solar headwinds remain.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sareptas depressed, volatile shares are drawing attention amid anticipation of DM1 and FSHD data and questions about ELEVIDYS demand and its regulatory path. Traders also debate whether Novartiss failed DM1 trial is a warning for Sareptas program or a limited read-through given different delivery technology, while frustration over persistent selling contrasts with hopes that upcoming data could rebuild confidence.

KraneShares Trust - KraneShares CSI China Internet ETF

KraneShares CSI China Internet ETF

KWEB is drawing attention around a potential rebound in beaten-down Chinese internet and tech stocks, with traders pointing to bullish options activity, technical support and rotation into China tech. Others remain skeptical, citing the ETFs persistent downtrend, weak market fundamentals and regulatory and geopolitical risks.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

SCHD is drawing attention as investors discuss a rotation between growth stocks and dividend-focused, defensive holdings, with many viewing the ETF as a steadier counterweight to tech volatility. Traders are split between buying dips for long-term income and questioning its recent pullbacks, which some attribute to rising Treasury yields making bonds more competitive.

Verizon Communications, Inc. is a holding company, which engages in the provision of communications, information, and entertainment products and services. It operates through the following business segments: Consumer and Business. The Consumer segment provides consumer-focused wireless and wire line communications services and products. The Business segment offers wireless and wireline communications services and products, including FWA broadband, data, video and conferencing services, corporate networking solutions, security and managed network services, local and long-distance voice services, and network access to deliver various IoT services and products. The company was founded in 1983 and is headquartered in New York, NY.

Verizon Communications Inc

Verizon Communications Inc.

Verizon shares sold off on concerns that SpaceXs planned acquisition of low-band spectrum could help Starlink Mobile compete with established wireless carriers. Traders are split between viewing the threat as a long-term risk to subscribers and pricing and calling the selloff overdone given the time and infrastructure needed to build a competing network, alongside Verizons cash flows and dividend.

Citigroup, Inc. is a holding company, which engages in the provision of financial products and services. It operates through the following segments: Services, Markets, Banking, Wealth, U.S. Personal Banking (USPB), and All Other. The Services segment includes Treasury and Trade Solutions (TTS) which provides an integrated suite of tailored cash management, trade, and working capital solutions to multinational corporations, financial institutions and public sector organizations, and Securities Services, which offers cross-border support for clients, providing on-the-ground local market expertise, post-trade technologies, customized data solutions, and a wide range of securities services solutions that can be tailored to meet client needs. The Markets segment provides corporate, institutional, and public sector clients around the world with a full range of sales and trading services across equities, foreign exchange, rates, spread products, and commodities. The Banking segment offers Investment Banking and Corporate Lending services. The Wealth segment includes Private Bank, Wealth at Work, and Citigold and provides financial services to a range of client segments through banking, lending, mortgages, investment, custody, and trust product offerings. The USPB segment includes Branded Cards and Retail Services, which have proprietary card portfolios and co-branded card portfolios within Branded Cards, and co-brand and private label relationships within Retail Services. The All Other segment consists of activities not assigned to the reportable operating segments, including certain unallocated costs of global functions, other corporate expenses, and net treasury results. The company was founded in 1812 and is headquartered in New York, NY.

Citigroup Inc

Rising yields and expectations ahead of Q3 earnings are weighing on bank stocks, with traders concerned about weaker lending and credit quality even as higher rates could support net interest income. Citi discussion is split between investors calling the pullback a buying opportunity and those anticipating cautious results or guidance.

Cash Cat

A sharp pullback after a speculative rally is driving discussion, with traders debating whether CASHCAT is a pump-and-dump with weak support or a dip worth buying. Bulls cite its Robinhood-chain presence and claimed launchpad-driven buybacks and burns, while those claims and rumors of exchange or executive support remain unverified.

Trulieve Cannabis Corp. engages in the cultivation, processing, manufacturing, and retail distribution of medical and adult-use cannabis products. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis Corp 

A DEA administrative law judges pause in the broader cannabis rescheduling proceeding has fueled debate over the delay and weighed on cannabis stocks, including Trulieve. Traders disagree on how exposed TRLV is: some see an industry-wide overreaction because much of Trulieves business is medical, while others remain concerned about uncertainty around Schedule III and related tax relief.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraud

Neumora Therapeutics (NASDAQ: NMRA) shareholders watched their investment collapse today after the company disclosed that navacaprant failed both Phase 3 KOASTAL-2 and KOASTAL-3 trials in major depressive disorder and announced an immediate workforce reduction of approximately 35%. Investors who...

NMRA SHAREHOLDER INVESTIGATION: SueWallSt Investigates Neumora Therapeutics for Possible Securities Law Violations

NMRA SHAREHOLDER INVESTIGATION: SueWallSt Investigates Neumora Therapeutics for Possible Securities Law Violations NMRA SHAREHOLDER INVESTIGATION: SueWallSt Investigates Neumora Therapeutics for Possible Securities Law Violations PR Newswire NEW YORK, June 17, 2026 Neumora Therapeutics...

Neumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA)

Neumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA) Neumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA) PR Newswire NEW YORK, June 16...

Neumora Stock Plunges 49% After Late-Stage Depression Drug Failure

NMRA stock sinks 49% after phase III depression studies show navacaprant's failure to meet key goals, leading to discontinuation of its development.

NMRA Stock On Track For Worst Day In 1.5 Years — Neumora Therapeutics' Lead Depression Drug Fails Late Stage Trials

Equity

The company described the results as disappointing and added that it is immediately discontinuing development of navacaprant.


Neumora Therapeutics (NMRA) Projected to Post Quarterly Earnings on Monday

Neumora Therapeutics (NASDAQ:NMRA) will be releasing its Q1 2026 earnings after the market closes on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-neumora-therapeutics-inc-stock...

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the nine brokerages that are covering the firm, Marketbeat reports...

Q2 EPS Forecast for Neumora Therapeutics Boosted by Analyst

Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) - Equities researchers at HC Wainwright increased their Q2 2026 earnings per share (EPS) estimates for shares of Neumora Therapeutics in a...

Guggenheim Reaffirms "Buy" Rating for Neumora Therapeutics (NASDAQ:NMRA)

Guggenheim reiterated a "buy" rating and issued a $14.00 target price on shares of Neumora Therapeutics in a report on Tuesday...

Neumora Therapeutics' (NMRA) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC reissued a "buy" rating and issued a $8.00 price objective on shares of Neumora Therapeutics in a research note on Tuesday...

Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. The firm offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. It focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.

Neumora Therapeutics Inc.

Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$0.4757
Prev Close	$0.4798
Open	$0.4701
Dividend Yield	0.00%
50-Day Moving Average	$1.16
Beta	1.43
Avg. Volume	1.7M
PE Ratio	-0.39

52-Week High	$3.65
52-Week Low	$0.4504
Market Capitalization	$90.15M
EPS (Annual)	-$1.45
Price to Book	2.00
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

NMRA Fundamentals